The company said its diluted net income for Q2 2025 (3 months) was $31,558 thousand ($0.05 per share), compared with $145,904 thousand ($0.21 per share) a year earlier, and its diluted FFO as Adjusted was $0.46 per share ($0.45 a year earlier).

1. 01

   The company said its diluted net income for Q2 2025 (3 months) was $31,558 thousand ($0.05 per share), compared with $145,904 thousand ($0.21 per share) a year earlier, and its diluted FFO as Adjusted was $0.46 per share ($0.45 a year earlier).

2. 02

   Healthpeak reaffirmed its full-year 2025 diluted FFO as Adjusted guidance of $1.81 to $1.87 per share and updated its diluted Nareit FFO outlook from $1.81 to $1.87 to $1.78 to $1.84 per share, the company said.

3. 03

   The company said it entered into 2 new development agreements in Q2 2025 to support Northside Hospital's outpatient expansion in Atlanta, with a combined projected cost of $148 million, and that Northside affiliates had pre-leased 78% of each building.

4. 04

   Healthpeak said it repurchased 3.9 million shares at a weighted average price of $18.22 per share, totaling $72 million, in April 2025, and repaid $452 million 4.0% senior notes at maturity in June 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.